Inovio Pharmaceuticals (INO: AMEX) is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio’s proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio’s clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. SNNLive spoke to Joseph Kim, PhD at the 2012 NIBA Conference in New Orleans.
In this interview, Dr. Kim talks about Inovio’s work to develop treatments for various cancers and infectious diseases. “We are very excited to have three programs in phase 2 efficacy trials… current phase 2 studies ongoing now against cervical cancer, dysplasia, leukemia… as well as hepatitis C.” Dr. Kim goes on to explain what Inovio’s work means: “Most preventive childhood vaccines use immune responses to generate antibodies against those bugs. For cancer vaccines or chronic immune therapies… you need to generate very strong T-cell responses. And our platform has been the most powerful platform in generating those very important T-cells in human trials.”
For more information about Inovio, be sure to pick up the latest issue of Micro-Cap Review to read Inovio’s story, “An Emerging Revolution in Vaccine Development”. SNNLive welcomes back Dr. Joseph Kim, CEO of Inovio Pharmaceuticals.
Micro-Cap Review Latest Issue
Cavaet Emptor or Buyer Beware by SNN Inc. CEO Sheldon “Shelly” Kraft
Check out the book "Caveat Emptor" written by CEO Sheldon Kraft, click on the image to view a preview and the full book can be purchased for $15.95.
There are some best practices and good hints on what to look out for in today’s volatile markets.